Timik Group is currently engaged in providing healthcare treatment and management solutions for treating, diagnosing and managing chronic diseases. These chronic conditions are, widespread and severely impact quality of life among those diagnosed with one or more of them. Timik Group is committed to pursuing and distributing medical innovations that provide new options for effective relief  to those with health challenges in one of these areas:

Lung and Ventilation

Respiratory disease refers to conditions affecting the organs and tissues that essentially make breathing possible. Diseases that affect the airways include asthma, chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, and cystic fibrosis. It has been estimated that one in ten deaths in Europe can be attributed to respiratory conditions.

We view this as a critical health issue and are actively engaged in seeking out effective therapies to help those who suffer from respiratory conditions treat and manage their challenges.

Löwenstein
Develops, produces and markets diagnostic and therapeutic system solutions of the best possible quality for the sleep and respiratory market. Their more than 130 years of experience and strict dedication inspires confidence. We have chosen them as a partner because of their innovative, economical and customized products that cover a broad therapy spectrum for the benefit of patient, doctor and cost carrier.

BD
BD and is a leading medical technology company that partners with customers and stakeholders to address the world’s most pressing and evolving health needs. Focusing on improving quality of patient care and safety to maximize outcomes in infections prevention, respiratory care, and acute care procedural effectiveness.
We have chosen them as a partner because of their range of mechanical ventilation products helping enhance patient care, optimize workflow efficiencies and support best practice strategies.

 

Sleep

Sleep-Disordered Breathing is a group of disorders characterized by abnormalities of respiratory pattern (pauses in breathing) or the quantity of ventilation during sleep. Obstructive sleep apnea is among the most common of such disorders. Sleep apnea is associated with an increased risk of hypertension, along with heart disease, depression and sleepiness-related accidents. Therapy requiring a CPAP machine and mask is often used to treat SDB. In developed countries, sleep apnea is reported to affect between 3 and 7% of middle aged men and 2–5% of women.

Löwenstein
Develops, produces and markets diagnostic and therapeutic system solutions of the best possible quality for the sleep and respiratory market. Their more than 130 years of experience and strict dedication inspires confidence. We have chosen them as a partner because of their innovative, economical and customized products that cover a broad therapy spectrum for the benefit of patient, doctor and cost carrier.

Itamar Medical
Itamar Medical is dedicated to research, development and commercialization of medical technology improving healthcare quality.
We have chosen them as a partner for their dedication to research and development of non-invasive recording, measurement and analysis of PAT® (Peripheral Arterial Tonometry) signal.

We will continue to monitor the market for the kind of technologies and design that give a high level of comfort and therapeutic benefit to our customers.

 

Health Research

ActiGraph
ActiGraph is dedicated and leading provider of objective physical activity and sleep/wake measurement solutions for global scientific community. We have chosen them as a partner for their dedication to provide highly accurate, innovative, and cost effective objective monitoring solutions. Helping clients to achieve their research and clinical data collection, analysis and management objectives.

We will continue to monitor the market for the kind of technologies and design that give a high level of comfort and therapeutic benefit to our customers.

 

Cardio

Sleep-related breathing disorders are among the medical challenges of modern society. Like cardiovascular diseases, they develop from hypertension, diabetes and lipometabolic disorders. An important risk factor shared by both sleep-related breathing disorders and cardiovascular diseases is overweight, a problem faced by an increasing proportion of society due to bad nutritional habits and lack of exercise. Current studies show that poor or inadequate sleep can affect metabolism in such a way that weight gain is encouraged. Prevention of cardiovascular disease is supported by the three pillars of nutrition, exercise and psychosocial balance. An urgently needed fourth pillar – sleep – should be added to make preventive measures even more effective. For patients who are already affected by a serious illness such as heart failure, physicians should determine whether nighttime breathing disorders are also present. If left untreated, they could have a negative effect on the patient’s prognosis.

SOMNOvent CR is a ventilator which provides automatically regulated pressure positive ventilation to patients with central sleep apnea syndrome accompanied by Cheyne-Stokes respiration and delivers combined treatment of co-prevalent obstructive sleep apnea syndrome and complex sleep apnea.

Ventilation therapy with SOMNOvent CR is anticyclical modulated ventilation (also known as adaptive servo ventilation) which continuously adjusts respiratory support to the needs of each patient. CR mode combines the advantages of intelligent reaction to central events, including those related to periodic breathing, with automatic regulation in response to obstructive events (similar to auto-CPAP therapy).

Löwenstein
Develops, produces and markets diagnostic and therapeutic system solutions of the best possible quality for the sleep and respiratory market. Their more than 130 years of experience and strict dedication inspires confidence. We have chosen them as a partner because of their innovative, economical and customized products that cover a broad therapy spectrum for the benefit of patient, doctor and cost carrier.

We will continue to monitor the market for the kind of technologies and design that give a high level of comfort and therapeutic benefit to our customers.

 

Neurology

A migraine headache is characterized by extremely painful throbbing or pulsing sensations in one area of the head and is often accompanied by vomiting, nausea and extreme sensitivity to light and sound. Migraines may be preceded or accompanied by sensory warning symptoms (aura) like flashes of light, blind spots, or tingling in the arms or legs.

Migraine sufferers can experience significant pain for hours to days and the pain can be so intense that they are immobilized and must remain in bed. There are medications that can help reduce the frequency and severity of migraines. Lifestyle changes and self-help remedies may also alleviate the length and severity of migraines. In Europe, migraines affect 12–28% of people at some point in their lives with about 6–15% of adult men and 14–35% of adult women getting at least one yearly. Migraine is ranked among the 12 most debilitating disorders, according to WHO.

Cefaly
Cefaly represents a serious breakthrough in the treatment of migraines. We have chosen to offer this product to our customers due to its success in clinical trials and its practical ease-of-use, a combination that makes it likely many migraine sufferers will gain effective relief with the device.

Migraine relief is an important focus area for us, due to its frequent occurrence in a significant percentage of the European population and its debilitating impact on quality of life. We will continue to seek out high-quality migraine solutions that can deliver real results.